{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:37:35Z","timestamp":1790105855402,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40119-025-00422-8","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T16:28:50Z","timestamp":1753806530000},"page":"327-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Transthyretin Kinetic Stabilizers for ATTR Amyloidosis"],"prefix":"10.1007","volume":"14","author":[{"given":"Jeffery W.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"422_CR1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"key":"422_CR2","doi-asserted-by":"publisher","first-page":"e008193","DOI":"10.1161\/circheartfailure.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15:e008193. https:\/\/doi.org\/10.1161\/circheartfailure.120.008193.","journal-title":"Circ Heart Fail"},{"key":"422_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jchf.2023.08.032","volume":"12","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Sultan MB, Gundapaneni B, et al. Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study. JACC Heart Fail. 2024;12:150\u201360. https:\/\/doi.org\/10.1016\/j.jchf.2023.08.032.","journal-title":"JACC Heart Fail"},{"key":"422_CR4","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ejhf.2974","volume":"25","author":"P Elliott","year":"2023","unstructured":"Elliott P, Gundapaneni B, Sultan MB, Ines M, Garcia-Pavia P. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms. Eur J Heart Fail. 2023;25:2060\u20134. https:\/\/doi.org\/10.1002\/ejhf.2974.","journal-title":"Eur J Heart Fail"},{"key":"422_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","volume":"264","author":"V Plant\u00e9-Bordeneuve","year":"2017","unstructured":"Plant\u00e9-Bordeneuve V, Gorram F, Salhi H, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol. 2017;264:268\u201376. https:\/\/doi.org\/10.1007\/s00415-016-8337-3.","journal-title":"J Neurol"},{"key":"422_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso FA, Judge DP, Ebede B, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24:194\u2013204. https:\/\/doi.org\/10.1080\/13506129.2017.1357545.","journal-title":"Amyloid"},{"key":"422_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40120-020-00180-w","volume":"9","author":"G Merlini","year":"2020","unstructured":"Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B. Evaluation of mortality during long-term treatment with tafamidis for transthyretin amyloidosis with polyneuropathy: clinical trial results up to 8.5 years. Neurol Ther. 2020;9:105\u201315. https:\/\/doi.org\/10.1007\/s40120-020-00180-w.","journal-title":"Neurol Ther"},{"key":"422_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/ejhf.3190","volume":"26","author":"M Grogan","year":"2024","unstructured":"Grogan M, Davis MK, Crespo-Leiro MG, et al. Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2024;26:612\u20135. https:\/\/doi.org\/10.1002\/ejhf.3190.","journal-title":"Eur J Heart Fail"},{"key":"422_CR9","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/ejhf.3330","volume":"26","author":"B Drachman","year":"2024","unstructured":"Drachman B, Damy T, Hanna M, Wang R, Angeli FS, Garcia-Pavia P. Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction. Eur J Heart Fail. 2024;26:2038\u201346. https:\/\/doi.org\/10.1002\/ejhf.3330.","journal-title":"Eur J Heart Fail"},{"key":"422_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/ehjqcco\/qcab031","volume":"8","author":"MH Rozenbaum","year":"2022","unstructured":"Rozenbaum MH, Garcia A, Grima D, et al. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and the open-label long-term extension studies. Eur Heart J Qual Care Clin Outcomes. 2022;8:529\u201338. https:\/\/doi.org\/10.1093\/ehjqcco\/qcab031.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"422_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.06.003","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Kristen AV, Drachman B, et al. Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with Tafamidis: an analysis from the transthyretin amyloidosis outcomes survey (THAOS). J Card Fail. 2024. https:\/\/doi.org\/10.1016\/j.cardfail.2024.06.003.","journal-title":"J Card Fail"},{"key":"422_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40120-018-0097-9","volume":"7","author":"R Mundayat","year":"2018","unstructured":"Mundayat R, Stewart M, Alvir J, et al. Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: an analysis from the transthyretin amyloidosis outcomes survey (THAOS). Neurol Ther. 2018;7:87\u2013101. https:\/\/doi.org\/10.1007\/s40120-018-0097-9.","journal-title":"Neurol Ther"},{"key":"422_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785\u201392. https:\/\/doi.org\/10.1212\/WNL.0b013e3182661eb1.","journal-title":"Neurology"},{"key":"422_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390:132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2305434.","journal-title":"N Engl J Med"},{"key":"422_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/13506129.2020.1808783","volume":"28","author":"LT Nelson","year":"2021","unstructured":"Nelson LT, Paxman RJ, Xu J, Webb B, Powers ET, Kelly JW. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Amyloid. 2021;28:24\u20139. https:\/\/doi.org\/10.1080\/13506129.2020.1808783.","journal-title":"Amyloid"},{"key":"422_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","volume":"74","author":"DP Judge","year":"2019","unstructured":"Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74:285\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.012.","journal-title":"J Am Coll Cardiol"},{"key":"422_CR17","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1073\/pnas.1300761110","volume":"110","author":"SC Penchala","year":"2013","unstructured":"Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A. 2013;110:9992\u20137. https:\/\/doi.org\/10.1073\/pnas.1300761110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"422_CR18","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","volume":"61","author":"M Miller","year":"2018","unstructured":"Miller M, Pal A, Albusairi W, et al. Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis. J Med Chem. 2018;61:7862\u201376. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00817.","journal-title":"J Med Chem"},{"key":"422_CR19","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1021\/bi500171j","volume":"53","author":"I Rappley","year":"2014","unstructured":"Rappley I, Monteiro C, Novais M, et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry. 2014;53:1993\u20132006. https:\/\/doi.org\/10.1021\/bi500171j.","journal-title":"Biochemistry"},{"key":"422_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/13506129.2020.1853094","volume":"28","author":"J Kelly","year":"2021","unstructured":"Kelly J, Powers E. Response. Amyloid. 2021;28:140\u20131. https:\/\/doi.org\/10.1080\/13506129.2020.1853094.","journal-title":"Amyloid"},{"key":"422_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/13506129.2022.2126308","volume":"30","author":"C Monteiro","year":"2023","unstructured":"Monteiro C, Mesgarzadeh JS, Anselmo J, et al. Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response. Amyloid. 2023;30:81\u201395. https:\/\/doi.org\/10.1080\/13506129.2022.2126308.","journal-title":"Amyloid"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00422-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00422-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00422-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:02:25Z","timestamp":1756220545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00422-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00422-8","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jeffery W. Kelly discovered tafamidis and receives sales royalties and sales milestone payments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This commentary is based on previously conducted studies and does not contain any new studies with human participants performed by the author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}